Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma

PHASE2

Phase

TERMINATED

Status

Enrollment

OTHER

Sponsor class

Stopped Paused due to COVID. A determination was made to stop the study because it would be impossible to reach the 65% resection rate as outlined in the protocol.

Conditions

Pancreatic Cancer

Interventions

DRUG: neoadjuvant mFOLFIRINOX
DRUG: Stereotactic body radiotherapy (SBRT)

Sponsor

Yale University